Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus

Renal allograft recipients with diabetes mellitus often demonstrate poorer clinical outcomes than nondiabetic patients. Basiliximab (Simulect super( registered )), a chimeric anti-interleukin-2 receptor monoclonal antibody, reduced the incidence of acute rejection in renal allograft recipients in 2...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Transplantation 2000-09, Vol.70 (5), p.784-790
Hauptverfasser:	THISTLETHWAITE, J. Richard, NASHAN, Björn, HALL, Michael, CHODOFF, Lawrence, LIN, Tsung-Hua
Format:	Artikel
Sprache:	eng
Schlagworte:	basiliximab Biological and medical sciences Immunomodulators Medical sciences Pharmacology. Drug treatments
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!